Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Antoni

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Annals of the Rheumatic Diseases|April 29, 2006
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitorsJ Fransen, C Antoni, P J Mease, et al.
Dermatology (Basel, Switzerland)|August 7, 1998
Graft-versus-host-like mucocutaneous eruptions with serological features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin's lymphomaV Mahler, C Antoni, G J Anhalt, et al.
Annals of the Rheumatic Diseases|January 29, 2005
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialC Antoni, G G Krueger, K de Vlam, et al.
Clinical and Experimental Immunology|June 1, 1993
A soluble form of the human transferrin receptor is released by activated lymphocytes in vitroW Woith, I Nüsslein, C Antoni, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 1996
In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effectsH M Lorenz, C Antoni, T Valerius, et al.
Lancet (London, England)|October 22, 1994
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritisM J Elliott, R N Maini, M Feldmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1999
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritisP Charles, M J Elliott, D Davis, et al.
Annals of the Rheumatic Diseases|February 15, 2005
Treatment continuation in patients receiving biological agents or conventional DMARD therapyA Zink, J Listing, S Kary, et al.
Arthritis and Rheumatism|September 29, 1998
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisR N Maini, F C Breedveld, J R Kalden, et al.
Arthritis and Rheumatism|August 1, 2007
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2D van der Heijde, A Kavanaugh, D D Gladman, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|April 29, 2006
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitorsJ Fransen, C Antoni, P J Mease, et al.
Dermatology (Basel, Switzerland)|August 7, 1998
Graft-versus-host-like mucocutaneous eruptions with serological features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin's lymphomaV Mahler, C Antoni, G J Anhalt, et al.
Annals of the Rheumatic Diseases|January 29, 2005
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialC Antoni, G G Krueger, K de Vlam, et al.
Clinical and Experimental Immunology|June 1, 1993
A soluble form of the human transferrin receptor is released by activated lymphocytes in vitroW Woith, I Nüsslein, C Antoni, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 1996
In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effectsH M Lorenz, C Antoni, T Valerius, et al.
Lancet (London, England)|October 22, 1994
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritisM J Elliott, R N Maini, M Feldmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1999
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritisP Charles, M J Elliott, D Davis, et al.
Annals of the Rheumatic Diseases|February 15, 2005
Treatment continuation in patients receiving biological agents or conventional DMARD therapyA Zink, J Listing, S Kary, et al.
Arthritis and Rheumatism|September 29, 1998
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisR N Maini, F C Breedveld, J R Kalden, et al.
Arthritis and Rheumatism|August 1, 2007
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2D van der Heijde, A Kavanaugh, D D Gladman, et al.
Pageof 4